Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2023-04-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
关于2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the expected daily related party transactions for the year 2023. It includes detailed information about the nature of these transactions, the parties involved, amounts, pricing policies, and the board and independent directors' approvals. The document is a formal disclosure of anticipated related party transactions, which is a regulatory requirement for listed companies to inform shareholders and the market about such transactions. It does not contain financial statements or comprehensive financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a voting result, management change, or earnings release. The document is a regulatory announcement about related party transactions, fitting best into the category of Regulatory Filings (RNS). The document length (8069 characters) and content confirm it is a full announcement, not a brief notice or a report publication announcement (RPA).
2023-04-27 Chinese
关于上海宣泰医药科技股份有限公司2022年度募集资金存放与使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report by a certified public accounting firm regarding the storage and usage of funds raised by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. in 2022. It references compliance with regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, specifically about the management and use of raised funds. The document includes detailed financial figures about the amount raised, usage, balance, and investment of idle funds. It is a specialized assurance report on the company's fundraising activities and fund management, not a full annual report or earnings release. This fits the definition of an Audit Report / Information (AR), as it is a standalone audit/verification report on a specific financial aspect (fundraising and fund usage) rather than a full annual report or other category. The document length and detail confirm it is the report itself, not just an announcement or certification letter. FY 2022
2023-04-27 Chinese
独立董事关于公司第一届董事会第十一次会议相关事项的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement of prior approval opinions from independent directors regarding matters to be discussed at the company's first board meeting's eleventh session. It specifically mentions the approval of the proposal to reappoint the audit firm for the 2023 fiscal year. The document is short (656 characters) and consists mainly of independent directors' endorsements rather than detailed financial data or audit results. It does not contain a full audit report or financial statements but is related to audit matters. Given the nature of the document as an approval opinion related to audit matters and the absence of detailed audit findings, it fits best under Audit Report / Information (AR) category, which includes audit-related documents excluding full annual reports. Confidence is high due to clear references to audit firm reappointment and independent directors' opinions. FY 2023
2023-04-27 Chinese
关于2022年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2022 annual profit distribution plan, including details on cash dividends per share, total dividend amount, and the decision-making process involving the board of directors, independent directors, and supervisory board. It explicitly states that the profit distribution plan requires approval at the 2022 annual general meeting. The document does not contain full financial statements or comprehensive financial performance data but focuses on dividend distribution details and procedural approvals. The document length is short (1547 characters) and is an announcement of a dividend plan rather than a full annual report or interim report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2023-04-27 Chinese
关于部分募投项目变更的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding changes to the use of proceeds from a previous fundraising project. It details the original and new project names, amounts of funds involved, reasons for the change, project descriptions, and approvals from the board, supervisory committee, independent directors, and the sponsor institution. The document also states that the change requires shareholder approval at the annual general meeting. The content focuses on the change in capital investment projects and the reallocation of raised funds, which is typical of a Capital/Financing Update. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or announcement of a report publication. The document length is over 6,000 characters and contains substantive details about the capital use change, not just a brief notice. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-04-27 Chinese
董事会议事规则（2023年4月）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors' of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. The content extensively details the qualifications, duties, meeting procedures, voting rules, confidentiality obligations, and other governance-related aspects of the company's board of directors. There is no financial data, audit information, or report publication mentioned. The document is a governance framework outlining internal rules and board structure. Therefore, it fits the category of Governance Information (CGR). The document length is sufficient and it is not a brief announcement or certification, so it is not RPA or RNS.
2023-04-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.